
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics is compelling because 4D-150 could materially change wet AMD care by pairing single-dose, intravitreal delivery with durable aflibercept expression and RNAi-mediated VEGF suppression, potentially reducing chronic anti-VEGF injections and preserving vision more consistently than episodic standard therapy. The Phase 2b PRISM data support that thesis, showing an 78% overall treatment burden reduction over 2 years, 2.7 mean supplemental injections per patient, and 87% reduction in the recently diagnosed subgroup, while maintaining visual acuity, anatomic control, and no new safety or intraocular inflammation after the initial 28 weeks. The company’s Phase 3 4FRONT-1 and 4FRONT-2 trials, with enrollment completed ahead of projections and a Week 52 BCVA non-inferiority endpoint, appear well positioned to de-risk the program and support a credible path to broader commercial adoption.
Bears say
4D Molecular Therapeutics is facing a bearish fundamental setup because its lead 4D-150 thesis depends on late-stage retina trials that may be difficult to interpret, with baseline imbalances, noisy endpoints, and non-comparable real-world treatment patterns all creating a high risk of misleading efficacy signals. The company is also exposed to commercialization uncertainty, since even competitors like Vabysmo and Eylea HD have reduced annual injection burden by only about one injection on average, while Medicare coverage could be challenged for a therapy framed around a roughly 5 year benefit horizon in an elderly patient base. Beyond clinical risk, the gene therapy field is crowded, 4D Molecular Therapeutics’s programs are still early, and it will likely need to raise more capital to keep advancing development.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About 4D Molecular Therapeutics (FDMT) Forecast
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares